Seattle firm Presage Biosciences has secured $6m in investment from Japanese pharma firm Takeda and US biopharma outfit Celgene. The money will be used to expand the use of Presage's CIVO platform, which tests microscopic amounts of drugs in cancer patients to determine their effects, ahead of phase I trials. In an interview with Reuters, CEO David Deamer said that he was "excited" about the funding round but declined to give further details on how much it would raise.
Seattle firm Presage Biosciences has secured $6m in investment from Japanese pharma firm Takeda and US biopharma outfit Celgene. The money will be used to expand the use of Presage's CIVO platform, which tests microscopic amounts of drugs in cancer patients to determine their effects, ahead of phase I trials. In addition, the company also revealed CSO Richard Klinghoffer had been appointed CEO, replacing Nathan Caffo, who will take on an advisory position.